Aktis Oncology (NASDAQ:AKTS) Receives Average Recommendation of “Moderate Buy” from Analysts

Aktis Oncology (NASDAQ:AKTS) has earned a consensus rating of “Moderate Buy” from the eight analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $34.00.

Several equities research analysts have weighed in on AKTS shares. William Blair began coverage on Aktis Oncology in a research note on Wednesday, April 29th. They set an “outperform” rating on the stock. Weiss Ratings upgraded Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. HC Wainwright raised their price target on shares of Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. Finally, Raymond James Financial initiated coverage on shares of Aktis Oncology in a report on Monday, June 15th. They set a “strong-buy” rating and a $40.00 price target for the company.

Aktis Oncology Stock Down 1.9%

Shares of AKTS stock traded down $0.54 during trading hours on Friday, reaching $27.88. The stock had a trading volume of 487,197 shares, compared to its average volume of 588,236. The firm has a market capitalization of $1.49 billion and a price-to-earnings ratio of -73.37. Aktis Oncology has a 12 month low of $14.72 and a 12 month high of $34.19. The stock has a fifty day simple moving average of $22.75.

Aktis Oncology (NASDAQ:AKTS) last issued its quarterly earnings data on Monday, March 30th. The technology company reported ($18.17) earnings per share (EPS) for the quarter. The company had revenue of $1.87 million during the quarter. As a group, equities analysts expect that Aktis Oncology will post -1.62 EPS for the current fiscal year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.